Dr. David Cunningham, MD
Claim this profileThe Royal Marsden NHS Foundation Trust
Studies Lymphoma
Studies Esophageal Cancer
11 reported clinical trials
27 drugs studied
Area of expertise
1Lymphoma
Stage IV
ARID1A positive
Stage III
2Esophageal Cancer
Stage III
Stage IV
HER2 positive
Clinical Trials David Cunningham, MD is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
TAK-676 + Pembrolizumab
for Metastatic Cancer
This trial is testing a new drug called dazostinag, alone and with another drug called pembrolizumab, to treat people with advanced solid tumors. It focuses on patients with specific types of head and neck cancer and colorectal cancer who have few other treatment options. The goal is to find a safe dose and see if the combination can help the immune system fight the cancer more effectively.
Recruiting2 awards Phase 1 & 210 criteria
More about David Cunningham, MD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments David Cunningham, MD has experience with
- Oxaliplatin
- Trastuzumab
- Rituximab
- Zanidatamab
- Cisplatin
- Tislelizumab
Breakdown of trials David Cunningham, MD has run
Lymphoma
Esophageal Cancer
- WaKING: Wnt and checKpoint INhibition in Gastric Cancer
- Zanidatamab + Chemotherapy ± Tislelizumab for Stomach and Esophageal Cancer
- Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer
Stomach Tumors
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Cunningham, MD specialize in?
David Cunningham, MD focuses on Lymphoma and Esophageal Cancer. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are ARID1A positive.
Is David Cunningham, MD currently recruiting for clinical trials?
Yes, David Cunningham, MD is currently recruiting for 4 clinical trials in Sutton Surrey. If you're interested in participating, you should apply.
Are there any treatments that David Cunningham, MD has studied deeply?
Yes, David Cunningham, MD has studied treatments such as Oxaliplatin, Trastuzumab, Rituximab.
What is the best way to schedule an appointment with David Cunningham, MD?
Apply for one of the trials that David Cunningham, MD is conducting.
What is the office address of David Cunningham, MD?
The office of David Cunningham, MD is located at: The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT United Kingdom. This is the address for their practice at the The Royal Marsden NHS Foundation Trust.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.